Menu
Česky English Deutsch
+420 532 23 1111

Mgr. Marek Borský

Vzdělání

1997 - Mgr. -  Molekulární biologie, PřF MU Brno

2008 - atestace "Vyšetřovací metody v klinické hematologii"

Pozice

1997 - 2002  Výzkumný ústav zdraví dítěte

2002 - dodnes, JOP s VŠ, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

2011 - dodnes, vedoucí sekce průtokové cytometrie, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

        Členství

Česká společnost pro analytickou cytometrii

Česká hematologická společnost

Vybrané publikace (2012 - 2017)

1.      Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. Br J Haematol. 2017 Sep;178(6):979–82.

2.      Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, et al. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. Leukemia [Internet]. 2017 Sep 22 [cited 2017 Sep 25]; Available from: http://www.nature.com.ezproxy.muni.cz/leu/journal/vaop/ncurrent/full/leu2017274a.html?foxtrotcallback=true

3.      Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget [Internet]. 2016 Aug 19 [cited 2016 Sep 6];5(0). Available from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=11388

4.      Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Br J Haematol. 2016 Sep 1;n/a-n/a.

5.      Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 Sep 22;128(12):1609–13.

6.      Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. Br J Haematol. 2016 Jul 29;

7.      Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, et al. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 2016 Jan 15;22(2):459–69.

8.      Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016 Apr 29;7(22):33016–24.

9.      Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, et al. Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. 2015 Aug 3;

10.    Sebejova L, Borsky M, Jaskova Z, Potesil D, Navrkalova V, Malcikova J, et al. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Experimental Hematology. 2014 Oct;42(10):867–74.e1.

11.    Potěšil D, Stejskal S, Borský M, Šimara P, Havelková M, Rázga F, et al. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. Analytical Letters. 2014 Apr 13;47(6):944–57.

12.    Musilova M( 1 ), Razga F( 1 2 ), Jurcek T( 1 ), Jeziskova I( 1 ), Borsky M( 1 ), Nemethova V( 1 2 ), et al. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. American Journal of Hematology. 2014 01;89(10):1016–7.

13.    Jurcek T( 1 ), Razga F( 1 2 ), Mazancova P( 1 ), Dvorakova D( 1 3 ), Borsky M( 1 ), Zackova D( 1 ), et al. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia. Leukemia and Lymphoma. 2014 01;55(8):1915–7.

14.    Mraz M, Kozubik K, Plevova K, Musilova K, Tichy B, Borsky M, et al. The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. LEUKEMIA RESEARCH. 2013 Jul;37(7):802–8.

15.    Dvorakova D, Racil Z, Borsky M, Robesova B, Jeziskova I, Razga F, et al. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. LEUKEMIA & LYMPHOMA. 2013 May;54(5):1056–60.

16.    Razga F, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, et al. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Molecular Diagnosis & Therapy. 2012 Jun 1;16(3):163–6.

17.    Mraz M, Dolezalova D, Plevova K, Kozubik K, Mayerova V, Cerna K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. BLOOD. 2012 Mar 1;119(9):2110–3.

  

Ke stažení
Informace o pohotovosti v Brně a Jihomoravském kraji